Список проголосовавших за комментарий " Notable movers of interest: TGT -4.7% on downside guidance due to softer-than-expected holiday sales<p>The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).</p><p><strong>Large Cap Gainers</strong></p><ul><li><strong>ASML</strong> (125.7 +8.45%): Reports Q4 EPS and revenue beats, guides Q1 revenues above consensus.</li><li><strong>LLY</strong> (77.11 +0.34%): Will acquire CoLucid Pharmaceuticals (<strong>CLCD</strong>) for $46.50/share or about $960 mln in cash.</li><li><strong>AGN</strong> (215.45 +0.31%): Co and Gedeon Richter report Phase III results for Ulipristal Acetate met all co-primary and secondary endpoints; agrees to admit securities law violations and pay a $15 mln penalty for disclosure failures in the wake of a hostile takeover bid.</li></ul><p><strong>Large Cap Losers</strong></p><ul><li><strong>NTRS</strong> (84.01 -4.7%): Reports Q4 EPS and revenue misses.</li><li><strong>TGT</strong> (67.62 -4.68%): Issues downside guidance for Q4 and FY17 due to softer-than-expected holiday sales.</li><li><strong>CSX</strong> (37.09 -2.64%): Shares down despite guiding Q1, FY17 EPS in-line.</li></ul><p><strong>Mid Cap Gainers</strong></p><ul><li><strong>JAZZ</strong> (125.95 +8.98%): FDA approves first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease.</li><li><strong>NBIX</strong> (41.74 +3.91%): Announces the top-line results from the Company's Phase II T-Forward study of INGREZZA.</li></ul><p><strong>Mid Cap Losers</strong></p><ul><li><strong>PSO</strong> (7.14 -28.53%): Provides FY16 trading statement, sees EPS above expectations, sees FY17 below consensus.</li><li><strong>CCJ</strong> (11.42 -13.95%): Expects 2016 adj net earning will be 'significantly lower' than analysts' earnings estimates; announces workforce reductions.</li><li><strong>KSS</strong> (39.71 -4.04%): Downgraded to Underperform from Neutral at Credit Suisse.</li></ul>"